These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1742754)

  • 1. Naloxone partly counteracts apomorphine side effects.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Clin Neuropharmacol; 1991 Oct; 14(5):442-9. PubMed ID: 1742754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
    Pahwa R; Koller WC; Trosch RM; Sherry JH;
    J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism.
    Corsini GU; Zompo MD; Cianchetti C; Mangoni A
    Psychopharmacologia; 1976 May; 47(2):169-73. PubMed ID: 1273213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
    Hauser RA; Isaacson S; Clinch T;
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs.
    Montastruc JL; Lapeyre-Mestre M; Llau ME; Senard JM; Rascol O; Montastruc P
    Clin Auton Res; 1994 Dec; 4(6):303-5. PubMed ID: 7711465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of naloxone to reverse apomorphine effects in humans.
    Rowbotham MC; Joseph MS; Jones RT; Keil LC
    Psychoneuroendocrinology; 1983; 8(1):95-102. PubMed ID: 6308702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical considerations in the use of apomorphine injectable.
    Bowron A
    Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: involvement of nitric oxide.
    Melis MR; Succu S; Iannucci U; Argiolas A
    Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):595-600. PubMed ID: 9151298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of time-of-day on the yawning response to apomorphine in normal subjects.
    Lal S; Tesfaye Y; Thavundayil JX; Skorzewska A; Schwartz G
    Neuropsychobiology; 2000; 41(4):178-80. PubMed ID: 10828726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: site of action in the brain.
    Melis MR; Stancampiano R; Gessa GL; Argiolas A
    Neuropsychopharmacology; 1992 Jan; 6(1):17-21. PubMed ID: 1315136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three preclinical models for nausea and vomiting assessment.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine.
    Axelsson P; Thörn SE; Lövqvist A; Wattwil L; Wattwil M
    Can J Anaesth; 2006 Apr; 53(4):370-4. PubMed ID: 16575035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of tolerance of dopaminergic responses in man.
    Lal S; Thavundayil JX; Ng Ying Kin NM; Dai X; Schwartz G; Montoya A
    J Neural Transm (Vienna); 2008 Aug; 115(8):1189-98. PubMed ID: 18506387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.